Taysha Gene Therapies TSHA
NASDAQ TSHA
$4.90 -0.09 (-1.80%)
As of: Sep 30, 2026 · 3:38 PM EDT

Taysha Gene Therapies (TSHA) Construction in Progress (2021 - 2022)

Updated

Taysha Gene Therapies' Construction in Progress was $62.1 million in Q3 2022, compared with $36,700 a year earlier and up 4.5% from the prior quarter.

Analysis

Taysha Gene Therapies (TSHA) Construction in Progress (2021 - 2022) Analysis & Trends

From Q2 2021 onward, Taysha Gene Therapies has reported Construction in Progress for 5 quarters.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn -
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn -
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn -
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn -
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn -
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn -
10 Taysha Gene Therapies 1.62 Bn 1.62 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2022 62.10 Mn
Jun 30, 2022 59.40 Mn
Mar 31, 2022 53.40 Mn
Sep 30, 2021 36,700.00
Jun 30, 2021 30.30 Mn
API Access

Taysha Gene Therapies Construction in Progress API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=construction-in-progress&ticker=TSHA&period=max&api_key=YOUR_API_KEY